Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

31 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

GSK Study ID 100386 & 100387 Persistence of immune response to TWINRIX™ ADULT Long Term Follow up Year 6 - Long Term Follow up Year 6

- 20-09-21 - 1 Formular, 5 Itemgruppen, 26 Datenelemente, 1 Sprache
Itemgruppen: Long Term Follow up Visit 8, Demographics, Laboratory Tests, Blood sample conclusion, Investigator Signature
Phase III, open, randomized study, in two centres, to demonstrate the equivalence of the 0, 12 month schedule to the 0, 6 month schedule with respect to the immunogenicity and to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A/ hepatitis B vaccine TWINRIX™ ADULT (720 EL. U. of hepatitis A antigen/ 20 μg of recombinant hepatitis B surface antigen) in healthy volunteers aged from 12 to 15 years inclusive. NCT00197171

Immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine Serious Long Term Follow-up 100577 - Long Term Follow-up Immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine 100577

- 27-07-17 - 1 Formular, 1 Itemgruppe, 9 Datenelemente, 1 Sprache
Itemgruppe: Long Term Follow-up
Study ID: 100577 Clinical Study ID: 100577 Study Title: Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289757 https://clinicaltrials.gov/ct2/show/NCT00289757 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Hepatitis A Vaccine, Inactivated Trade Name: Havrix Study Indication: Hepatitis A Documentation part: Tracking Document, Long Term Follow-up

Immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine Serious Long Term Follow-up 100576 - Long Term Follow-up Immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine 100576

- 27-07-17 - 1 Formular, 1 Itemgruppe, 9 Datenelemente, 1 Sprache
Itemgruppe: Long Term Follow-up
Study ID: 100576 (Y11) Clinical Study ID: 100576 Study Title: Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289757 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Hepatitis A Vaccine, Inactivated Trade Name: Havrix Study Indication: Hepatitis A Documentation part: Tracking Document, Long Term Follow-up

GSK Study ID 100386 & 100387 Persistence of immune response to TWINRIX™ ADULT Long Term Follow up Year 5 - Long Term Follow up Year 5

- 11-10-17 - 1 Formular, 6 Itemgruppen, 31 Datenelemente, 1 Sprache
Itemgruppen: Long Term Follow up Visit 7, Demographics, Laboratory Tests, Follow up Studies, Investigator Signature, Tracking Document
Phase III, open, randomized study, in two centres, to demonstrate the equivalence of the 0, 12 month schedule to the 0, 6 month schedule with respect to the immunogenicity and to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A/ hepatitis B vaccine TWINRIX™ ADULT (720 EL. U. of hepatitis A antigen/ 20 μg of recombinant hepatitis B surface antigen) in healthy volunteers aged from 12 to 15 years inclusive. NCT00197171

GSK Study ID 100406/004 Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster, Visit 1 - GSK Study ID 100406/004 Visit 1

- 23-10-17 - 1 Formular, 22 Itemgruppen, 235 Datenelemente, 1 Sprache
Itemgruppen: Informed Consent, Demographics, Eligibility determination, Inclusion criteria, Exclusion Criteria, Medical history, General medical history / physical examination, Pre-vaccination assessment, Laboratory tests, Blood sample, Urine sample (Pregnancy test – HCG), Pre-vaccination assessment, Vaccine adminstration, Reason not administered?, Adverse events - Post - vaccination oberservation, Measurement of mid upper arm circumference, Measurement of mid upper arm circumference, continued, Solicited adverse events - Local symptoms, Local symptoms, Solicited adverse events - General symptoms, General Symptoms, Contact person
A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00263679

GSK Study ID 100406/004 Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster Visit 2 - GSK Study ID 100406/004 Visit 2

- 18-10-17 - 1 Formular, 8 Itemgruppen, 38 Datenelemente, 1 Sprache
Itemgruppen: Check for Study Continuation, Pre-vaccination assessment, Laboratory tests, Blood sample, URINE SAMPLE (Pregnancy test – HCG), Vaccine adminstration, Reason not administered?, Adverse events - Post - vaccination oberservation
A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00263679

GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine (NCT00134719) - Extended Safety Follow-Up

- 02-04-19 - 1 Formular, 1 Itemgruppe, 33 Datenelemente, 1 Sprache
Itemgruppe: Follow-up
Study ID: 102370 (primary study) Clinical Study ID: 102370 Study Title: A multicentre when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00134719 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: BIO HIB-MENCY-TT; MenHibrix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis

Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers NCT00289718 - Long-Term Follow Up (Year 15; Study Conclusion) - Follow-Up Studies; Study Conclusion; Tracking Document; Diary Card

- 15-04-19 - 1 Formular, 10 Itemgruppen, 64 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Follow-Up Studies, Study Conclusion, Investigator signature, Tracking Document - Reason for non participation, Diary Card - Local Symptoms (at injection site), Diary Card - Other local symptoms, Diary Card - Medication, Diary Card - General Symptoms, Diary Card - Other general Symptoms
Study ID: 100556 (Y11) Clinical Study ID: 100556 Study Title: Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289718 Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers NCT00289718 - Long-Term Follow Up (Year 14; Study Conclusion) - Follow-Up Studies; Study Conclusion; Tracking Document; Diary Card

- 11-04-19 - 1 Formular, 10 Itemgruppen, 64 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Follow-Up Studies, Study Conclusion, Investigator signature, Tracking Document - Reason for non participation, Diary Card - Local Symptoms (at injection site), Diary Card - Other local symptoms, Diary Card - Medication, Diary Card - General Symptoms, Diary Card - Other general Symptoms
Study ID: 100556 (Y11) Clinical Study ID: 100556 Study Title: Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289718 Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers NCT00289718 - Long-Term Follow Up (Year 13; Study Conclusion) - Follow-Up Studies; Study Conclusion; Tracking Document; Diary Card

- 11-04-19 - 1 Formular, 10 Itemgruppen, 64 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Follow-Up Studies, Investigator signature, Study Conclusion, Tracking Document - Reason for non participation, Diary Card - Local Symptoms, Diary Card - Other local symptoms, Diary Card - Medication, Diary Card - General Symptoms, Diary Card - Other general Symptoms
Study ID: 100556 (Y11) Clinical Study ID: 100556 Study Title: Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289718 Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Immunogenicity, safety and reactogenicity of combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) in healthy children (100565) - Study Conclusion - Follow-Up Studies; Study Conclusion; Tracking Document; Diary Card

- 10-04-19 - 1 Formular, 10 Itemgruppen, 63 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Follow-Up Studies, Investigator signature, Study Conclusion, Tracking Document - Reason for non participation, Diary Card - Local Symptoms, Diary Card - Other local symptoms, Diary Card - Medication, Diary Card - General Symptoms, Diary Card - Other general Symptoms
Study ID: 100565 Clinical Study ID: 100565 Study Title: An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers NCT00289718 - Long-Term Follow Up (Year 11) - Follow-Up Studies; Study Conclusion

- 08-04-19 - 1 Formular, 4 Itemgruppen, 20 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Follow-Up Studies, Study Conclusion, Investigator signature
Study ID: 100556 (Y11) Clinical Study ID: 100556 Study Title: Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289718 Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video